Clinical performance of [18F]piflufolastat PET/CT on a 194-cm LAFOV PET/CT system in prostate cancer
Pierpaolo Alongi, Agostino Chiaravalloti, Simone Morea, Daniele Di Biagio · 2026
Read Clinical performance of [18F]piflufolastat PET/CT on a 194-cm LAFOV PET/CT system in prostate cancer by Pierpaolo Alongi, Agostino Chiaravalloti, Simone Morea, Daniele Di Biagio (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13421277.txt.
Description
Pierpaolo Alongi and colleagues tested total-body PET/CT in 2026 for prostate cancer detection using a fluorine-18 piflufolastat tracer on a 194-centimeter scanner. The team reviewed 103 patients scanned for initial staging or suspected recurrence, judging detection rates and how results tracked prostate-specific antigen levels.
Scans were positive in 88.3 percent overall and in all staging cases, with primary lesions, lymph nodes, and bone the top sites, while higher PSA strongly predicted positive scans in recurrence. Urologists gain a high-yield staging tool whose value rises steeply with PSA in suspected recurrence.
Catalog record
| CREATOR | Pierpaolo Alongi, Agostino Chiaravalloti, Simone Morea, Daniele Di Biagio |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |